Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Otrivine Adult Nasal Spray.
| Pharmaceutical Form |
|---|
|
Nasal spray, solution. The spray is a clear, colourless solution. |
Xylometazoline Hydrochloride 0.1% w/v.
For excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Xylometazoline |
Xylometazoline acts directly on α-adrenoreceptors but does not act on β-receptors. When used topically as a nasal decongestant, xylometazoline acts rapidly and provides long-lasting relief. Onset of action is within minutes, the decongestant effect being prolonged and lasting for up to 10 hours. |
| List of Excipients |
|---|
|
Benzalkonium chloride |
Bottle: Low density polyethylene
Cap: High density polyethylene
Spray valve and capillary: Low density polyethylene
Carton: Cardboard
Pack size: 10 ml.
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
PL 44673/0149
1st October 1997/19th August 2010
| Drug | Countries | |
|---|---|---|
| OTRIVINE | Ireland, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
